B. Riley Securities Reinstates Buy on CytoSorbents, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities analyst Justin Walsh has reinstated CytoSorbents (NASDAQ:CTSO) with a Buy rating and maintained a $4 price target.
September 07, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CytoSorbents has been reinstated with a Buy rating by B. Riley Securities, with a maintained price target of $4.
The reinstatement of the Buy rating by B. Riley Securities indicates a positive outlook for CytoSorbents. The maintained price target of $4 also suggests that the analyst believes the stock is undervalued at current levels, which could lead to upward price movement in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100